Optimizing Pediatric HIV-1 Therapy (OPH)

Funding: NIH 2 R01 HD023412-19
Time period: 05/01/06-4/30/2011
 

This trial will involve 0-3 month olds started on HAART for 24 months and then randomized to withdrawn versus continued HAART to determine whether interruption is a viable approach to spare antiretrovirals for a few years in pediatric HIV-1.

Link to study workspace (for those with access): https://catalysttools.washington.edu/

Comments are closed.